Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

This study tests a combination of two drugs — camrelizumab (an immunotherapy) and dalpiciclib (a targeted therapy) — given before surgery (neoadjuvant treatment) in patients with head and neck squamous cell carcinoma that can be surgically removed. **You may be eligible if...** - You are 18 or older with a newly diagnosed, surgically removable head and neck squamous cell carcinoma (not nasopharyngeal cancer) - Your cancer has not spread to distant parts of the body - You are willing to undergo surgery - Your blood counts and organ function are in acceptable range **You may NOT be eligible if...** - You have had other cancers in the past 5 years (some minor skin cancers may be OK) - You have an active autoimmune disease requiring systemic treatment - You have had prior immunotherapy, anti-EGFR therapy, or other targeted cancer treatments - You have significant heart problems, uncontrolled diabetes or high blood pressure, or active infections including HIV, hepatitis B or C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.